PE20191134A1 - Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f - Google Patents
Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1fInfo
- Publication number
- PE20191134A1 PE20191134A1 PE2019001167A PE2019001167A PE20191134A1 PE 20191134 A1 PE20191134 A1 PE 20191134A1 PE 2019001167 A PE2019001167 A PE 2019001167A PE 2019001167 A PE2019001167 A PE 2019001167A PE 20191134 A1 PE20191134 A1 PE 20191134A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridinoylpiperidine
- compositions
- methods related
- refers
- ray diffraction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A FORMAS PSEUDOPOLIMORFICAS DE LA SAL DE HEMISUCCINATO DE 2,4,6-TRIFLUORO-N-[6-(1-METIL-PIPERIDIN-4-CARBONIL)-PIRIDIN-2-IL]-BENZAMIDA (COMPUESTO I) O HEMISUCCINATO DE LASMIDITAN, TALES COMO: A) LA FORMA D CUYO PATRON DE DIFRACCION DE RAYOS X INCLUYE PICOS A 18.7, 26.5, 27, 27.5 Y 27.8 GRADOS 2THETA; II) LA FORMA F CUYO PATRON DE DIFRACCION DE RAYOS X INCLUYE PICOS A 12.3, 17.1, 20.6, 24.2 Y 26.9 GRADOS 2THETA; III) LA FORMA E. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHAS FORMAS PSEUDOPOLIMORFICAS. EL LASMIDITAN ACTIVA LOS RECEPTORES 5-HT1F SIENDO UTIL EN EL TRATAMIENTO O PREVENCION DE LA MIGRANA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430662P | 2016-12-06 | 2016-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191134A1 true PE20191134A1 (es) | 2019-09-02 |
Family
ID=60972336
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002466A PE20241297A1 (es) | 2016-12-06 | 2017-12-05 | Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f |
| PE2019001167A PE20191134A1 (es) | 2016-12-06 | 2017-12-05 | Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002466A PE20241297A1 (es) | 2016-12-06 | 2017-12-05 | Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US11053214B2 (es) |
| EP (1) | EP3551617B1 (es) |
| JP (4) | JP2020500936A (es) |
| KR (4) | KR20190075130A (es) |
| CN (3) | CN110291079A (es) |
| AU (1) | AU2017373784B2 (es) |
| BR (1) | BR112019010934A2 (es) |
| CA (1) | CA3043772C (es) |
| CL (1) | CL2019001426A1 (es) |
| CO (1) | CO2019005290A2 (es) |
| CR (1) | CR20190251A (es) |
| CY (1) | CY1124540T1 (es) |
| DK (1) | DK3551617T3 (es) |
| DO (1) | DOP2019000139A (es) |
| EA (1) | EA201991112A1 (es) |
| EC (1) | ECSP19040190A (es) |
| ES (1) | ES2889476T3 (es) |
| HR (1) | HRP20211557T1 (es) |
| HU (1) | HUE056820T2 (es) |
| IL (1) | IL266598B2 (es) |
| JO (1) | JOP20190129B1 (es) |
| LT (1) | LT3551617T (es) |
| MA (1) | MA52920B1 (es) |
| MD (1) | MD3551617T2 (es) |
| MX (2) | MX388091B (es) |
| MY (1) | MY196855A (es) |
| NZ (1) | NZ752906A (es) |
| PE (2) | PE20241297A1 (es) |
| PH (1) | PH12019501252B1 (es) |
| PL (1) | PL3551617T3 (es) |
| PT (1) | PT3551617T (es) |
| RS (1) | RS62415B1 (es) |
| SI (1) | SI3551617T1 (es) |
| TN (1) | TN2019000174A1 (es) |
| TW (1) | TWI671290B (es) |
| UA (1) | UA124433C2 (es) |
| WO (1) | WO2018106657A1 (es) |
| ZA (1) | ZA201903449B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20171742T4 (hr) | 2009-04-02 | 2021-08-06 | Colucid Pharmaceuticals, Inc. | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| TWI829107B (zh) * | 2019-07-09 | 2024-01-11 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
| CN111004214B (zh) * | 2019-11-22 | 2021-06-08 | 广东东阳光药业有限公司 | 吡啶酰基哌啶衍生物及其用途 |
| US12271057B1 (en) | 2019-12-20 | 2025-04-08 | The Uab Research Foundation | Chromatic aberration tuning ophthalmic corrector lens methods |
| AU2022270144A1 (en) | 2021-05-07 | 2023-10-26 | Eli Lilly And Company | Taste masked compostions of 2,4,6-trifluoro- n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2- ylj-benzamide hemisuccinate, and orally disentegrating tablet comprising the same |
| CN116270505A (zh) * | 2021-12-20 | 2023-06-23 | 南京科默生物医药有限公司 | 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| US20060178349A1 (en) | 2005-01-24 | 2006-08-10 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID |
| HRP20171742T4 (hr) | 2009-04-02 | 2021-08-06 | Colucid Pharmaceuticals, Inc. | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom |
| WO2011123654A1 (en) * | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
| WO2012163365A1 (en) | 2011-06-01 | 2012-12-06 | Concit Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
| CN113173910A (zh) | 2016-07-15 | 2021-07-27 | 杭州领业医药科技有限公司 | 一种受体激动剂的晶型及其制备方法和药物组合物 |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
-
2017
- 2017-12-05 PE PE2023002466A patent/PE20241297A1/es unknown
- 2017-12-05 DK DK17829372.6T patent/DK3551617T3/da active
- 2017-12-05 MY MYPI2019003189A patent/MY196855A/en unknown
- 2017-12-05 EA EA201991112A patent/EA201991112A1/ru unknown
- 2017-12-05 JP JP2019551251A patent/JP2020500936A/ja active Pending
- 2017-12-05 KR KR1020197016255A patent/KR20190075130A/ko not_active Ceased
- 2017-12-05 PE PE2019001167A patent/PE20191134A1/es unknown
- 2017-12-05 SI SI201730881T patent/SI3551617T1/sl unknown
- 2017-12-05 BR BR112019010934A patent/BR112019010934A2/pt not_active Application Discontinuation
- 2017-12-05 MX MX2019006520A patent/MX388091B/es unknown
- 2017-12-05 UA UAA201905483A patent/UA124433C2/uk unknown
- 2017-12-05 CN CN201780075750.7A patent/CN110291079A/zh active Pending
- 2017-12-05 IL IL266598A patent/IL266598B2/en unknown
- 2017-12-05 PH PH1/2019/501252A patent/PH12019501252B1/en unknown
- 2017-12-05 HU HUE17829372A patent/HUE056820T2/hu unknown
- 2017-12-05 CR CR20190251A patent/CR20190251A/es unknown
- 2017-12-05 MA MA52920A patent/MA52920B1/fr unknown
- 2017-12-05 RS RS20211233A patent/RS62415B1/sr unknown
- 2017-12-05 KR KR1020217025499A patent/KR20210102497A/ko not_active Ceased
- 2017-12-05 KR KR1020227046438A patent/KR20230008257A/ko not_active Ceased
- 2017-12-05 CA CA3043772A patent/CA3043772C/en active Active
- 2017-12-05 TN TNP/2019/000174A patent/TN2019000174A1/en unknown
- 2017-12-05 KR KR1020257014875A patent/KR20250070124A/ko active Pending
- 2017-12-05 MD MDE20191169T patent/MD3551617T2/ro unknown
- 2017-12-05 JO JOP/2019/0129A patent/JOP20190129B1/ar active
- 2017-12-05 HR HRP20211557TT patent/HRP20211557T1/hr unknown
- 2017-12-05 AU AU2017373784A patent/AU2017373784B2/en active Active
- 2017-12-05 NZ NZ752906A patent/NZ752906A/en unknown
- 2017-12-05 US US16/467,208 patent/US11053214B2/en active Active
- 2017-12-05 WO PCT/US2017/064652 patent/WO2018106657A1/en active Application Filing
- 2017-12-05 CN CN202210944298.6A patent/CN115385893A/zh active Pending
- 2017-12-05 MX MX2021014139A patent/MX392547B/es unknown
- 2017-12-05 PL PL17829372T patent/PL3551617T3/pl unknown
- 2017-12-05 EP EP17829372.6A patent/EP3551617B1/en active Active
- 2017-12-05 TW TW106142535A patent/TWI671290B/zh active
- 2017-12-05 ES ES17829372T patent/ES2889476T3/es active Active
- 2017-12-05 PT PT17829372T patent/PT3551617T/pt unknown
- 2017-12-05 LT LTEPPCT/US2017/064652T patent/LT3551617T/lt unknown
- 2017-12-05 CN CN202210944373.9A patent/CN115385894A/zh active Pending
-
2019
- 2019-05-23 CO CONC2019/0005290A patent/CO2019005290A2/es unknown
- 2019-05-27 CL CL2019001426A patent/CL2019001426A1/es unknown
- 2019-05-30 DO DO2019000139A patent/DOP2019000139A/es unknown
- 2019-05-30 ZA ZA2019/03449A patent/ZA201903449B/en unknown
- 2019-06-06 EC ECSENADI201940190A patent/ECSP19040190A/es unknown
-
2021
- 2021-09-22 JP JP2021153729A patent/JP2022000451A/ja active Pending
- 2021-10-05 CY CY20211100864T patent/CY1124540T1/el unknown
-
2023
- 2023-06-26 JP JP2023104019A patent/JP7561240B2/ja active Active
-
2024
- 2024-09-20 JP JP2024163884A patent/JP2024178323A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191134A1 (es) | Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2023002982A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
| CL2018003577A1 (es) | Piridina substituida como inhibidor de dnmt1. | |
| CL2015003491A1 (es) | Compuestos químicos. | |
| CL2018003429A1 (es) | Compuestos novedosos como inhibidores de la autotaxina y composiciones farmacéuticas que los comprenden. | |
| CO2019003162A2 (es) | Formas cristalinas y salinas de compuestos agonistas de ppar | |
| CL2017002244A1 (es) | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015). | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| MX2019001096A (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| CL2015002386A1 (es) | Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo. | |
| UY34062A (es) | ?compuestos heterocíclicos fusionados moduladores de canal ionico para el tratamiento de enfermedades que responden al bloqueo de canal de sodio?. | |
| MX2016011037A (es) | Compuestos de fosfonato para el tratamiento de trastornos mediados por complemento. | |
| MX2017014818A (es) | Agonistas de triazol del receptor apj. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CL2016001283A1 (es) | Derivado de urea o sal farmacológicamente aceptable del mismo | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| CO2017000222A2 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
| EP3412344A4 (en) | FIRE-DELAYING COMPOSITION | |
| BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
| JOP20190053A1 (ar) | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |